uchealth.org
Personalized mRNA Cancer Vaccine Significantly Reduces Melanoma Recurrence in Phase 3 Trial
A personalized mRNA cancer vaccine, developed by Moderna and Merck, has demonstrated significant success in late-stage clinical trials for melanoma. When combined with existing immunotherapy, the vacc